April 30, 2025
Medical Management May

Medical Management means using medicines and other non-invasive therapies to relieve symptoms. The FDA approved Camzyos in 2022 and It's exciting that new treatments for HCM are being studied! 


HCM can cause various symptoms depending on how stiff the heart is, how much scarring (fibrosis) there is, and whether there is obstruction. Some people have no noticeable symptoms. Common symptoms are chest pain/pressure, shortness of breath, lightheadedness, fatigue, palpitations, and brain fog. Syncope (fainting) is dramatic but not as common as the other symptoms.


Medications are the first-line treatment for symptoms of HCM. If patients can't take one class of medication, they can try a medication from a different class.


Here are some medications used to treat HCM and what they're for:


  • Beta Blockers - make your heart beat slower and relax better. They allow the heart to fill more completely between beats. They can lower blood pressure and relieve symptoms.

  • Calcium Channel Blockers - used to lower blood pressure and slow the heart rate. May reduce symptoms from obstruction in HCM.

  • Myosin Inhibitors - cause the heart to beat with less force. They may reduce obstruction and septal thickness in some patients. Camzyos (mavacamten) is the first of this class of medication. For more information, click HERE

  • Antiarrhythmics - help to restore normal rhythm in the heart.

  • Blood Thinners - anticoagulants and anti-platelets make it harder for blood to clot. They are prescribed to reduce the risk of stroke. This risk is higher in patients with afib, aflutter, and artificial heart valves. 

  • Diuretics, or "water pills," help the kidneys get rid of extra water and salt, reducing swelling in the body.

  • Sodium Channel Blockers - may reduce gradient in obstructive HCM and can treat chest pain. Some also act as antiarrhythmics.

  • Antibiotics - treat or prevent bacterial infections. In HCM, they may be given before dental work to prevent infective endocarditis.


To learn more and see the side effects of these medications, click HERE.



HCMA Blog

Cytokinetics Logo of a green
By Erica Friedman May 14, 2025
Positive clinical trial endpoints for MAPLE-HCM study announced by Cyctokonetics for aficamten in obstructive hypertrophic cardiomyopathy
A Caucasian hand with a pen rests on a clipboard that holds paper with writing.
By Gordon Fox May 14, 2025
In the third of a series about decision-making and risk in HCM, Gordon Fox explains where risk data comes from and how to understand it.
4 diverse people stand under the mathmateical formula 25% = 1 in 4.
By Gordon Fox May 13, 2025
In part three of this series on decision making in HCM, Gordon Fox discusses how medical professionals define risk within a patient population, and what the different kinds of risk mean for a patient.
More Posts